serum biomarkers: Phospholipids
https://www.sciencedirect.com/science/a ... Btl2YkeCPg
From this study, we can conclude that the pathogenesis of MSs was associated with changes in the lipid profile and that patients with MSs have a significantly different PL profile compared to healthy controls. Our results showed that the phospholipidomic signature of MSs is significantly different from that of healthy controls, in particular for the PE, PC, LPE and ether-linked PE and PC species.
Based on the comparison of MSs_Rel and MSs_Rem, our models had less discriminating power, and the species that showed significant differences were mainly PC species, particularly PC(38:1). PC and PE plasmalogens, as well as PC and PE species bearing PUFA, had significantly lower levels in MSs disease and MSs_Rel and MSs_Rem.
PE(40:10) and PC(38:1) may be considered as possible serum biomarkers of this disease due to their significant variations in patients with MSs and may be suitable for clinical applications.
These results provide new insights on changes in the lipidome profile in MSs and may help improve our understanding of the characteristics of MSs pathogenesis.
Clinical lipidomics is one of the best approaches to better understand these disease-induced changes and find suitable biomarkers for personalized MSs medicine.